364 related articles for article (PubMed ID: 17577041)
1. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Sultana A; Smith CT; Cunningham D; Starling N; Neoptolemos JP; Ghaneh P
J Clin Oncol; 2007 Jun; 25(18):2607-15. PubMed ID: 17577041
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Yip D; Karapetis C; Strickland A; Steer CB; Goldstein D
Cochrane Database Syst Rev; 2006 Jul; (3):CD002093. PubMed ID: 16855985
[TBL] [Abstract][Full Text] [Related]
3. WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Yip D; Karapetis C; Strickland A; Steer CB; Goldstein D
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD002093. PubMed ID: 19821291
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
6. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Tu C; Zheng F; Wang JY; Li YY; Qian KQ
Asian Pac J Cancer Prev; 2015; 16(14):5681-6. PubMed ID: 26320435
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Li Q; Yan H; Liu W; Zhen H; Yang Y; Cao B
PLoS One; 2014; 9(8):e104346. PubMed ID: 25093849
[TBL] [Abstract][Full Text] [Related]
9. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
[TBL] [Abstract][Full Text] [Related]
10. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
Sultana A; Tudur Smith C; Cunningham D; Starling N; Neoptolemos JP; Ghaneh P
Br J Cancer; 2008 Jul; 99(1):6-13. PubMed ID: 18577990
[TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Jin SF; Fan ZK; Pan L; Jin LM
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
14. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for advanced pancreatic cancer.
Chua YJ; Cunningham D
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):327-48. PubMed ID: 16549331
[TBL] [Abstract][Full Text] [Related]
16. [Possibilities of palliation in pancreatic cancer].
Di Costanzo F; Sdrobolini A; Gasperoni S
Tumori; 1999; 85(1 Suppl 1):S47-53. PubMed ID: 10235081
[TBL] [Abstract][Full Text] [Related]
17. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
18. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
Dig Liver Dis; 2014 May; 46(5):452-9. PubMed ID: 24565950
[TBL] [Abstract][Full Text] [Related]
19. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
[TBL] [Abstract][Full Text] [Related]
20. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Pelzer U; Schwaner I; Stieler J; Adler M; Seraphin J; Dörken B; Riess H; Oettle H
Eur J Cancer; 2011 Jul; 47(11):1676-81. PubMed ID: 21565490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
